Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates.
Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates.
复制标题
实体器官移植受者的免疫检查点抑制剂：临床更新。
DOI：
10.4285/kjt.22.0013
复制
发表时间：
2022-06-30
影响因子：
--
通讯作者：
Murakami N
中科院分区：
文献类型：
--
作者：
Kawashima S;Joachim K;Abdelrahim M;Abudayyeh A;Jhaveri KD;Murakami N
移植护理随着临床经验的增加和免疫抑制治疗的改善而不断发展。随着人口老龄化和长期生存率的提高，移植患者的护理变得更加复杂，因为移植后合并症，虚弱和癌症患病率增加。免疫检查点抑制剂（ICI）已成为非移植患者中许多癌症的标准治疗选择，但由于可能破坏免疫耐受性，在移植患者中使用ICI具有挑战性。然而，在过去的几年里，ICIs也逐渐开始用于移植患者。在这项研究中，我们回顾了目前使用的ICI后，所有实体器官移植程序（肾，肝，心脏和肺）。越来越多的数据表明，免疫抑制剂的类型和数量可能会影响免疫治疗后排斥反应的风险。移植患者的癌症免疫治疗可能是选定患者的可行选择;然而，需要在特定器官移植受者中进行前瞻性试验。
Transplant care continues to advance with increasing clinical experience and improvements in immunosuppressive therapy. As the population ages and long-term survival improves, transplant patient care has become more complex due to comorbidities, frailty, and the increased prevalence of cancer posttransplantation. Immune checkpoint inhibitors (ICIs) have become a standard treatment option for many cancers in non-transplant patients, but the use of ICIs in transplant patients is challenging due to the possibility of disrupting immune tolerance. However, over the past few years, ICIs have gradually started to be used in transplant patients as well. In this study, we review the current use of ICIs after all solid organ transplantation procedures (kidney, liver, heart, and lung). Increasing data suggest that the type and number of immunosuppressants may affect the risk of rejection after immunotherapy. Immunotherapy for cancer in transplant patients may be a feasible option for selected patients; however, prospective trials in specific organ transplant recipients are needed.